DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mercaptopurine (Mercaptopurine) - Off Label Use - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Off Label Use (24)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Mercaptopurine where reactions include off label use. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Mercaptopurine side effects in female

Reported by a consumer/non-health professional from United States on 2012-08-22

Patient: female, weighing 37.2 kg (81.9 pounds)

Reactions: Tooth Loss, Respiratory Rate Increased, Pain, Off Label Use, Thinking Abnormal, Malaise, Euphoric Mood, Palpitations, Heart Rate Increased, Pancreatitis, Dizziness

Drug(s) suspected as cause:
Actiq
    Indication: Pain

Actiq
    Indication: Crohn's Disease

Mercaptopurine

Other drugs received by patient: Ciprofloxacin HCL; Morphine; Flagyl; Pentasa



Possible Mercaptopurine side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-17

Patient: female

Reactions: Off Label Use, Ileostomy, Intestinal Operation, Pelvic Pouch Procedure, Pouchitis, Treatment Failure

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Remicade
    Indication: Colitis Ulcerative

Humira
    Dosage: 40 mg/0.8 ml pre-filled syringe
    Start date: 2009-08-01

Humira
    Indication: Pouchitis
    Start date: 2012-06-06

Humira
    Dosage: 40 mg/0.8 ml pre-filled syringe
    Indication: Colitis Ulcerative
    Start date: 2009-08-01

Humira
    Start date: 2012-06-06

Mercaptopurine
    Dosage: 40 mg/0.8 ml pre-filled syringe
    Indication: Product Used FOR Unknown Indication



Possible Mercaptopurine side effects in female

Reported by a consumer/non-health professional from United States on 2012-08-16

Patient: female, weighing 37.2 kg (81.9 pounds)

Reactions: Respiratory Rate Increased, Tooth Loss, Pain, Off Label Use, Thinking Abnormal, Malaise, Euphoric Mood, Palpitations, Heart Rate Increased, Dizziness, Pancreatitis

Drug(s) suspected as cause:
Mercaptopurine

Actiq
    Indication: Pain

Actiq
    Indication: Crohn's Disease

Other drugs received by patient: Pentasa; Ciprofloxacin HCL; Flagyl



Possible Mercaptopurine side effects in female

Reported by a physician from Lebanon on 2012-07-20

Patient: female

Reactions: Off Label Use, Cytomegalovirus Chorioretinitis

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide

Methotrexate
    Dosage: 4 doses of 5 g/m2
    Indication: Acute Lymphocytic Leukaemia

Prednisone
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Cytarabine

Daunorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Asparaginase
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: total dose limited to 4.6 g/m2
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Indication: Acute Lymphocytic Leukaemia



Possible Mercaptopurine side effects in 12 year old female

Reported by a health professional (non-physician/pharmacist) from Brazil on 2012-06-01

Patient: 12 year old female

Reactions: Off Label Use, Muscular Weakness

Drug(s) suspected as cause:
Teniposide
    Dosage: for 3 weeks.

Methotrexate
    Dosage: 2 g/m2/wk for 3 wks, 40 mg/m2/wk for 6 wks and after 80 wks 40 mg/m2/wk every 6 wks until 120 wks.

Mercaptopurine
    Dosage: 75 mg/m2/day for 3 wks and unknown dose for 6 wks. after 80 wks, daily every six wks.

Cyclophosphamide
    Dosage: for four consecutive days

Dexamethasone
    Dosage: for seven days until the 120th week.

Etoposide
    Dosage: for three consecutive days

Cytarabine
    Dosage: 250 mg/m2/dose/wk for 3 wks and 15 g/m2/day for two consecutive days for 6 wks.

Vincristine
    Dosage: after 80 wks, 1.5 mg/m2 pulses every six wks.



Possible Mercaptopurine side effects in 15 year old male

Reported by a health professional (non-physician/pharmacist) from Brazil on 2012-06-01

Patient: 15 year old male

Reactions: Off Label Use, Muscular Weakness

Drug(s) suspected as cause:
Etoposide
    Dosage: for three consecutive days

Vincristine
    Dosage: after 80 wks, 1.5 mg/m2 pulses every six wks.

Teniposide
    Dosage: for 3 weeks.

Dexamethasone
    Dosage: for seven days until the 120th week.

Methotrexate
    Dosage: 2 g/m2/wk for 3 wks, 40 mg/m2/wk for 6 wks and after 80 wks 40 mg/m2/wk every 6 wks until 120 wks.

Mercaptopurine
    Dosage: 75 mg/m2/day for 3 wks and unknown dose for 6 wks. after 80 wks, daily every six wks.

Cyclophosphamide
    Dosage: for four consecutive days

Cytarabine
    Dosage: 250 mg/m2/dose/wk for 3 wks and 15 g/m2/day for two consecutive days for 6 wks.



Possible Mercaptopurine side effects in 12 year old female

Reported by a health professional (non-physician/pharmacist) from Brazil on 2012-06-01

Patient: 12 year old female

Reactions: Off Label Use, Muscular Weakness

Drug(s) suspected as cause:
Mercaptopurine
    Dosage: 75 mg/m2/day for 3 wks and unknown dose for 6 wks. after 80 wks, daily every six wks.
    Indication: Acute Lymphocytic Leukaemia

Teniposide
    Dosage: for 3 weeks.
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: after 80 wks, 1.5 mg/m2 pulses every six wks.
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: for four consecutive days
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: 250 mg/m2/dose/wk for 3 wks and 15 g/m2/day for two consecutive days for 6 wks.
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: for seven days until the 120th week.
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 2 g/m2/wk for 3 wks, 40 mg/m2/wk for 6 wks and after 80 wks 40 mg/m2/wk every 6 wks until 120 wks.
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: for three consecutive days
    Indication: Acute Lymphocytic Leukaemia



Possible Mercaptopurine side effects in 15 year old female

Reported by a health professional (non-physician/pharmacist) from Brazil on 2012-06-01

Patient: 15 year old female

Reactions: Off Label Use, Muscular Weakness

Drug(s) suspected as cause:
Methotrexate
    Dosage: 2 g/m2/wk for 3 wks, 40 mg/m2/wk for 6 wks and after 80 wks 40 mg/m2/wk every 6 wks until 120 wks.

Dexamethasone
    Dosage: for seven days until the 120th week.

Cyclophosphamide
    Dosage: for four consecutive days

Etoposide
    Dosage: for three consecutive days

Vincristine
    Dosage: after 80 wks, 1.5 mg/m2 pulses every six wks.

Mercaptopurine
    Dosage: 75 mg/m2/day for 3 wks and unknown dose for 6 wks. after 80 wks, daily every six wks.

Teniposide
    Dosage: for 3 weeks.

Cytarabine
    Dosage: 250 mg/m2/dose/wk for 3 wks and 15 g/m2/day for two consecutive days for 6 wks.



Possible Mercaptopurine side effects in 13 year old female

Reported by a health professional (non-physician/pharmacist) from Brazil on 2012-06-01

Patient: 13 year old female

Reactions: Off Label Use, Muscular Weakness

Drug(s) suspected as cause:
Vincristine
    Dosage: after 80 wks, 1.5 mg/m2 pulses every six wks.

Teniposide
    Dosage: for 3 weeks.

Methotrexate
    Dosage: 2 g/m2/wk for 3 wks, 40 mg/m2/wk for 6 wks and after 80 wks 40 mg/m2/wk every 6 wks until 120 wks.

Cytarabine
    Dosage: 250 mg/m2/dose/wk for 3 wks and 15 g/m2/day for two consecutive days for 6 wks.

Etoposide
    Dosage: for three consecutive days.

Mercaptopurine
    Dosage: 75 mg/m2/day for 3 wks and unknown dose for 6 wks. after 80 wks, daily every six wks.

Cyclophosphamide
    Dosage: for four consecutive days.

Dexamethasone
    Dosage: for seven days until the 120th week.



Possible Mercaptopurine side effects in 16 year old female

Reported by a health professional (non-physician/pharmacist) from Brazil on 2012-06-01

Patient: 16 year old female

Reactions: Off Label Use, Muscular Weakness

Drug(s) suspected as cause:
Etoposide
    Dosage: for three consecutive days

Cytarabine
    Dosage: 250 mg/m2/dose/wk for 3 wks and 15 g/m2/day for two consecutive days for 6 wks.

Methotrexate
    Dosage: 2 g/m2/wk for 3 wks, 40 mg/m2/wk for 6 wks and after 80 wks 40 mg/m2/wk every 6 wks until 120 wks.

Teniposide
    Dosage: for 3 weeks.

Cyclophosphamide
    Dosage: for four consecutive days

Vincristine
    Dosage: after 80 wks, 1.5 mg/m2 pulses every six wks.

Dexamethasone
    Dosage: for seven days until the 120th week.

Mercaptopurine
    Dosage: 75 mg/m2/day for 3 wks and unknown dose for 6 wks. after 80 wks, daily every six wks.



Possible Mercaptopurine side effects in 14 year old female

Reported by a health professional (non-physician/pharmacist) from Brazil on 2012-06-01

Patient: 14 year old female

Reactions: Off Label Use, Muscular Weakness

Drug(s) suspected as cause:
Etoposide
    Dosage: for three consecutive days

Teniposide
    Dosage: for 3 weeks.

Cyclophosphamide
    Dosage: for four consecutive days

Mercaptopurine
    Dosage: 75 mg/m2/day for 3 wks and unknown dose for 6 wks. after 80 wks, daily every six wks.

Dexamethasone
    Dosage: for seven days until the 120th week.

Cytarabine
    Dosage: 250 mg/m2/dose/wk for 3 wks and 15 g/m2/day for two consecutive days for 6 wks.

Vincristine
    Dosage: after 80 wks, 1.5 mg/m2 pulses every six wks.

Methotrexate
    Dosage: 2 g/m2/wk for 3 wks, 40 mg/m2/wk for 6 wks and after 80 wks 40 mg/m2/wk every 6 wks until 120 wks.



Possible Mercaptopurine side effects in 16 year old female

Reported by a health professional (non-physician/pharmacist) from Brazil on 2012-06-01

Patient: 16 year old female

Reactions: Off Label Use, Muscular Weakness

Drug(s) suspected as cause:
Cytarabine
    Dosage: 250 mg/m2/dose/wk for 3 wks and 15 g/m2/day for two consecutive days for 6 wks.
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Dosage: 75 mg/m2/day for 3 wks and unknown dose for 6 wks. after 80 wks, daily every six wks.
    Indication: Acute Lymphocytic Leukaemia

Teniposide
    Dosage: for 3 weeks.
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: after 80 wks, 1.5 mg/m2 pulses every six wks.
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: for seven days until the 120th week.
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 2 g/m2/wk for 3 wks, 40 mg/m2/wk for 6 wks and after 80 wks 40 mg/m2/wk every 6 wks until 120 wks.
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: for four consecutive days
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: for three consecutive days
    Indication: Acute Lymphocytic Leukaemia



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-24

Patient:

Reactions: Off Label Use, Hyperglycaemia, Ketoacidosis

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, re-induction
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: days 22,29, 32, previous protocol, re-induction

Methotrexate
    Dosage: weekly; previous protocol; continuation phase

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 every 8 weeks during 1 year, previous protocol, continuation phase

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 on days 1, 8, previous protocol, consolidation phase

Methotrexate
    Dosage: age dependent dose on days 1, 22, previous protocol, re-induction phase

Prednisone
    Dosage: days 1-29, previous protocol, remission induction

Vincristine

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 on days 2,4,6,8,10,12 previous protocol, reinduction

Cytarabine
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Cytarabine
    Dosage: hd; in h patients; days 43, 44; previous protocol; re-induction phase

Mercaptopurine
    Dosage: daily, previous protocol, continuation phase

Dexamethasone
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, remission induction

Vincristine

Mercaptopurine
    Dosage: days 1-14, previous protocol, consolidation phase
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age dependent dose on days 1, 22 (extra 8, 15), previous protocol, remission induction

Cytarabine
    Dosage: every 8 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Elspar
    Dosage: 10,000 u/m2 or 25, 000u/m2 on days 2,4,6,8,10,12 previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Prednisone
    Dosage: days 1-29, previous protocol, re-induction induction
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Elspar
    Dosage: 25,000u/m2 weeklyduring first 19 weeks; previous protocol; continuation

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 thrice weekly(reinduction i, ii), weekly (reinduction i) previous protocol

Methotrexate
    Dosage: previous protocol, continuation phase
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age dependent dose on days 1,8,previous protocol, consolidation

Etoposide
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, re-induction

Cytoxan
    Dosage: stable/high, every 8 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Leucovorin Calcium; Cotrim



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-24

Patient:

Reactions: Off Label Use, Leukaemia

Drug(s) suspected as cause:
Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, remission induction

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 on days 2,4,6,8,10,12 previous protocol, reinduction

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Cytoxan
    Dosage: stable/high, every 8 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age dependent dose on days 1,8,previous protocol, consolidation

Dexamethasone
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age dependent dose on days 1, 22 (extra 8, 15), previous protocol, remission induction

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 on days 1, 8, previous protocol, consolidation phase

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, re-induction
    Indication: Acute Lymphocytic Leukaemia

Elspar
    Dosage: 25,000u/m2 weeklyduring first 19 weeks; previous protocol; continuation

Cytarabine
    Dosage: every 8 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: weekly; previous protocol; continuation phase

Prednisone
    Dosage: days 1-29, previous protocol, re-induction induction
    Indication: Acute Lymphocytic Leukaemia

Prednisone
    Dosage: days 1-29, previous protocol, remission induction

Elspar
    Dosage: 10,000 u/m2 or 25, 000u/m2 on days 2,4,6,8,10,12 previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: hd; in h patients; days 43, 44; previous protocol; re-induction phase

Methotrexate
    Dosage: previous protocol, continuation phase
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age dependent dose on days 1, 22, previous protocol, re-induction phase

Mercaptopurine
    Dosage: days 1-14, previous protocol, consolidation phase
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, remission induction

Vincristine
    Dosage: every 4 weeks, previous protocol, continuation

Cytarabine
    Dosage: days 22,29, 32, previous protocol, re-induction

Cytarabine
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Mercaptopurine
    Dosage: daily, previous protocol, continuation phase

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 every 8 weeks during 1 year, previous protocol, continuation phase

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, re-induction induction
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, re-induction

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 thrice weekly(reinduction i, ii), weekly (reinduction i) previous protocol

Other drugs received by patient: Cotrim; Leucovorin Calcium



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-24

Patient:

Reactions: Off Label Use, Diabetes Mellitus

Drug(s) suspected as cause:
Methotrexate
    Dosage: weekly; current protocol; continuation phase

Cytoxan
    Dosage: on days 22, 29, 32, previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Dosage: days 22-35, current protocol, remission-induction

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: low risk 8 mg/m2, 5 days, stable/high risk 12 mg/m2, every 4 weeks, current protocol, continuation

Methotrexate
    Dosage: weekly; previous protocol; continuation phase

Radiotherapy
    Indication: Acute Lymphocytic Leukaemia

Elspar
    Dosage: 10,000 u/m2 or 25, 000u/m2 on days 2,4,6,8,10,12 previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 on days 1, 8, previous protocol, consolidation phase

Mercaptopurine
    Dosage: 50-70 mg/m2, daily, current protocol, continuation phase
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on days 22, 29, 32, previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age dependent dose on days 1, 22 (extra 8, 15), previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Prednisone
    Dosage: days 1-29, previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: days 1-8, 15-22, current protocol, remission-induction
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Cotrim; Leucovorin Calcium



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-24

Patient:

Reactions: Off Label Use, Treatment Failure

Drug(s) suspected as cause:
Mercaptopurine
    Dosage: daily, previous protocol, continuation phase

Dexamethasone
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Prednisone
    Dosage: days 1-29, previous protocol, re-induction
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: every 8 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 on days 1, 8, previous protocol, consolidation phase

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, re-induction
    Indication: Acute Lymphocytic Leukaemia

Cytoxan
    Dosage: stable/high, every 8 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Elspar

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, re-induction

Elspar

Methotrexate
    Dosage: age dependent dose on days 1,8,previous protocol, consolidation

Methotrexate
    Dosage: weekly; previous protocol; continuation phase

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, remission induction

Elspar
    Dosage: 10,000 u/m2 or 25, 000u/m2 on days 2,4,6,8,10,12 previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Elspar

Cytarabine
    Dosage: days 22,29, 32, previous protocol, re-induction

Etoposide
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 every 8 weeks during 1 year, previous protocol, continuation phase

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, re-induction induction
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, remission induction

Vincristine
    Dosage: every 4 weeks, previous protocol, continuation

Cytarabine
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Methotrexate
    Dosage: age dependent dose on days 1, 22, previous protocol, re-induction phase

Prednisone
    Dosage: days 1-29, previous protocol, remission induction

Cytarabine
    Dosage: hd; in h patients; days 43, 44; previous protocol; re-induction phase

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Mercaptopurine
    Dosage: days 1-14, previous protocol, consolidation phase
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: previous protocol, continuation phase
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age dependent dose on days 1, 22 (extra 8, 15), previous protocol, remission induction

Other drugs received by patient: Cotrim; Leucovorin Calcium



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-24

Patient:

Reactions: Off Label Use, Neuropathy Peripheral, Cerebrovascular Accident

Drug(s) suspected as cause:
Cytarabine
    Dosage: hd; in h patients; days 43, 44; previous protocol; re-induction phase
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 on days 1, 8, previous protocol, consolidation phase

Mercaptopurine
    Dosage: days 1-14, previous protocol, consolidation phase

Prednisone
    Dosage: days 1-29, previous protocol, re-induction
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: every 4 weeks, previous protocol, continuation

Elspar
    Dosage: 10,000 u/m2 or 25, 000u/m2 on days 2,4,6,8,10,12 previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Cytoxan
    Dosage: stable/high, every 8 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, remission induction

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 every 8 weeks during 1 year, previous protocol, continuation phase

Prednisone
    Dosage: days 1-29, previous protocol, remission induction

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, re-induction

Methotrexate
    Dosage: age dependent dose on days 1,8,previous protocol, consolidation

Methotrexate
    Dosage: weekly; previous protocol; continuation phase

Cytarabine
    Dosage: every 8 weeks, previous protocol, continuation

Cytarabine
    Dosage: days 22,29, 32, previous protocol, re-induction

Dexamethasone
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, re-induction
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, re-induction induction
    Indication: Acute Lymphocytic Leukaemia

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 on days 2,4,6,8,10,12 previous protocol, reinduction

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 thrice weekly(reinduction i, ii), weekly (reinduction i) previous protocol

Elspar
    Dosage: 25,000u/m2 weeklyduring first 19 weeks; previous protocol; continuation

Cytarabine
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: every 4 weeks, previous protocol, continuation

Methotrexate
    Dosage: age dependent dose on days 1, 22 (extra 8, 15), previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: previous protocol, continuation phase

Methotrexate
    Dosage: age dependent dose on days 1, 22, previous protocol, re-induction phase

Mercaptopurine
    Dosage: daily, previous protocol, continuation phase
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Cotrim; Leucovorin Calcium



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-24

Patient:

Reactions: Off Label Use, Treatment Related Secondary Malignancy

Drug(s) suspected as cause:
Vincristine
    Dosage: every 4 weeks, previous protocol, continuation

Elspar
    Dosage: 25,000u/m2 weeklyduring first 19 weeks; previous protocol; continuation

Methotrexate
    Dosage: previous protocol, continuation phase
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, remission induction

Cytoxan
    Dosage: stable/high, every 8 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: days 22,29, 32, previous protocol, re-induction

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Mercaptopurine
    Dosage: days 1-14, previous protocol, consolidation phase
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 every 8 weeks during 1 year, previous protocol, continuation phase

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, re-induction
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, re-induction

Methotrexate
    Dosage: age dependent dose on days 1,8,previous protocol, consolidation

Methotrexate
    Dosage: age dependent dose on days 1, 22 (extra 8, 15), previous protocol, remission induction

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, remission induction

Prednisone
    Dosage: days 1-29, previous protocol, re-induction
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, re-induction induction
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: every 8 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 thrice weekly(reinduction i, ii), weekly (reinduction i) previous protocol

Cytarabine
    Dosage: hd; in h patients; days 43, 44; previous protocol; re-induction phase

Dexamethasone
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 on days 1, 8, previous protocol, consolidation phase

Elspar
    Dosage: 10,000 u/m2 or 25, 000u/m2 on days 2,4,6,8,10,12 previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 on days 2,4,6,8,10,12 previous protocol, reinduction

Mercaptopurine
    Dosage: daily, previous protocol, continuation phase

Methotrexate
    Dosage: age dependent dose on days 1, 22, previous protocol, re-induction phase

Methotrexate
    Dosage: weekly; previous protocol; continuation phase

Prednisone
    Dosage: days 1-29, previous protocol, remission induction

Other drugs received by patient: Cotrim; Leucovorin Calcium



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-18

Patient:

Reactions: Off Label Use, Fungal Infection, Bacterial Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: days 1, 8 (15)

Vincristine
    Dosage: days 1, 8, 15, 22

Etoposide
    Dosage: days 22, 29, 32
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: standard risk/high risk: 300 mg/m2 /dose every 4 weeks

Cyclophosphamide
    Dosage: standard risk/high risk: 300 mg/m2 /dose every 8 weeks
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: every 4 weeks
    Indication: Acute Lymphocytic Leukaemia

Prednisone
    Dosage: days 1-29

Elspar
    Dosage: days 2, 4, 6, 8, 10, 12
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: high dosehigh risk: 3 g/m2 every 12 hours, days 43, 44

Cytarabine
    Dosage: days 22, 29, 32

Methotrexate
    Dosage: every 8 weeks during first year (hd; l: 1.5 g/m 2, s: 2 g/m 2, h: 5 g/m 2)

Cytarabine
    Dosage: days 22, 29, 32

Methotrexate
    Dosage: l: every 6 - 8 weeks during first year, s/h: every 4 weeks during first year

Prednisone
    Dosage: days 1-29
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: days 1, 8

Vincristine
    Dosage: days 1, 8, 15, 22
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: days 1, 22, extra methotrexate on days 8 and 15 for patients with cns-2/ cns-3 status
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: 30 mg/m 2 /day, weekly

Doxorubicin HCL
    Dosage: days 1, 8 (15)
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: every 4 weeks

Etoposide
    Dosage: days 22, 29, 32

Mercaptopurine
    Dosage: days 1- 14
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Dosage: daily

Methotrexate
    Dosage: days 1, 22

Elspar
    Dosage: days 2, 4, 6, 8, 10, 12

Cytarabine
    Dosage: standard risk/high risk: 300 mg/m 2 /dose every 8 weeks
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: days 1, 8 (hd; l: 1.5 g/m 2, s: 2 g/m 2, h: 5 g/m 2)

Other drugs received by patient: Cotrim; Leucovorin Calcium



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-16

Patient:

Reactions: Off Label Use, Neuropathy Peripheral, Hyperglycaemia, Neutropenic Sepsis, Pancreatitis, Cerebrovascular Accident, Ketoacidosis, Convulsion

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: on days 1, 8, current protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, re-induction

Doxorubicin HCL
    Dosage: in low, standard and high risk patients; day 1 (reinduction i, ii) and days 1, 8 (in reinduction i)

Cytarabine
    Dosage: hd; in s/h patients; days 15-16 in reinduction ii; current protocol
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age dependent dose on day 8,15,29, current protocol, consolidation

Vincristine
    Dosage: on days 1, 8, 15, 22, current protocol, remission induction

Cytarabine
    Dosage: every 4 weeks, current protocol, continuation

Mercaptopurine
    Dosage: daily, previous protocol, continuation phase
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Dosage: days 15-70, current protocol, consolidation phase

Mercaptopurine
    Dosage: 50-70 mg/m2, daily, current protocol, continuation phase

Methotrexate
    Dosage: age dependent dose on days 1, 22, previous protocol, re-induction phase

Methotrexate
    Dosage: weekly; previous protocol; continuation phase

Methotrexate
    Dosage: weekly; current protocol; continuation phase

Doxorubicin HCL
    Dosage: in s/h patients; every 3 weeks during first 16 weeks, continuation phase,current protocol

Vincristine
    Dosage: every 4 weeks, current protocol, continuation phase

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 on days 2,4,6,8,10,12 previous protocol, reinduction

Elspar
    Dosage: 25,000u/m2 weeklyduring first 19 weeks; previous protocol; continuation

Cytarabine
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Cytarabine
    Dosage: days 22,29, 32, previous protocol, re-induction

Mercaptopurine
    Dosage: days 1-14, previous protocol, consolidation phase

Methotrexate
    Dosage: age dependent dose on days 1; current protocol, re-induction phase
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 every 8 weeks during 1 year, previous protocol, continuation phase

Prednisone
    Dosage: days 1-28, current protocol, remission induction

Prednisone
    Dosage: days 1-29, previous protocol, remission induction

Cyclophosphamide
    Dosage: stable/high, every 4 weeks, current protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l:2.5 g/m2, s/h: 5 g/m2 on days 1, 15,29,43,57, current protocol, consolidation phase

Elspar
    Dosage: 10,000 u/m2 or 25, 000u/m2 on days 2,4,6,8,10,12 previous protocol, remission induction

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, remission induction

Cyclophosphamide
    Dosage: stable/high, every 8 weeks, previous protocol, continuation

Methotrexate
    Dosage: age dependent dose on days 1, 22 (extra 8, 15), previous protocol, remission induction

Dexamethasone
    Dosage: low risk 8 mg/m2, 5 days, stable/high risk 12 mg/m2, every 4 weeks, current protocol, continuation

Doxorubicin HCL
    Dosage: on days 1, 8 and extra on day 15, previous protocol, remission induction

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, remission induction
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: on days 23-26, 29-32, current protocol, remission-induction

Etoposide
    Dosage: every 4 weeks, previous protocol, continuation

Mercaptopurine
    Dosage: days 22-35, current protocol, remission-induction

Methotrexate
    Dosage: age dependent dose on days 1,8,previous protocol, consolidation

Vincristine
    Dosage: on days 1, 8, 15, 22, previous protocol, re-induction induction

Vincristine
    Dosage: every 4 weeks, previous protocol, continuation

Cytarabine
    Dosage: hd; in h patients; days 43, 44; previous protocol; re-induction phase

Cyclophosphamide
    Dosage: on day 26, current protocol, remission-induction

Methotrexate
    Dosage: age dependent dose every 4 weeks during 1 year current protocol, continuation phase

Dexamethasone
    Dosage: every 4 weeks, previous protocol, continuation
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l:1.5 g/m2, s: 2g/m2, h: 5 g/m2 on days 1, 8, previous protocol, consolidation phase

Prednisone
    Dosage: days 1-29, previous protocol, re-induction induction
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: on days 1, 8, 15, current protocol, re-induction induction

Elspar
    Dosage: 10,000 u/m2 or 25,000u/m2 thrice weekly(reinduction i, ii), weekly (reinduction i) previous protocol
    Indication: Acute Lymphocytic Leukaemia

Elspar
    Dosage: 10,000 u/m2 on days 2,4,6,8,10,12 (15, 17, 19)current protocol, remission induction

Cytarabine
    Dosage: every 8 weeks, previous protocol, continuation

Etoposide
    Dosage: on days 22, 29, 32, previous protocol, re-induction
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: previous protocol, continuation phase

Methotrexate
    Dosage: age dependent dose on days 1, 15 (extra on 8, 22), current protocol, remission-induction

Dexamethasone
    Dosage: days 1-8, 15-22, current protocol, remission-induction

Other drugs received by patient: Cotrim; Leucovorin Calcium



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-16

Patient:

Reactions: Off Label Use, Bacterial Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Methotrexate
    Dosage: days 1, 8

Etoposide
    Dosage: days 22, 29, 32
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age-dependent days 1, 22 (8, 15) extra on days 8 and 15 for patients with cns-2 or cns-3 status

Methotrexate
    Dosage: weekly

Methotrexate
    Dosage: high dose, l: 1.5 g/m2, s: 2 g/m2, h: 5 g/m2 on days 1, 8

Elspar
    Dosage: days 2, 4, 6, 8, 10, 12, 10000 u/m2/dose for l/s and 250000 u/m2/dose intramuscular for h
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: high dose, l: 1.5 g/m2, s: 2 g/m2, h: 5 g/m2 on days 1, 8, every 8 weeks during first year

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: every 4 weeks
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: s, h: 300mg/m2/dose every 4 weeks
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Dosage: days 22, 29, 32

Cytarabine
    Dosage: high dose 3g/m2 q 12 h on days 43, 44

Mercaptopurine
    Dosage: daily
    Indication: Acute Lymphocytic Leukaemia

Prednisone TAB
    Indication: Acute Lymphocytic Leukaemia

Etoposide
    Dosage: every 8 weeks

Vincristine
    Dosage: days 1, 8, 15, 22

Methotrexate
    Dosage: days 1, 22

Mercaptopurine

Cyclophosphamide
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: l: every 6-8 weeks during first year, s/h: every 4 weeks during first year
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Cotrim



Possible Mercaptopurine side effects in

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-05-16

Patient:

Reactions: Off Label Use, Bacterial Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Prednisone TAB
    Dosage: days 1-28
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Dosage: on days 1, 8, 15, 22,

Elspar
    Dosage: 10,000 u/m2 thrice weekly (in reinduction i), s/h: 25,000 u/m2 thrice weekly (in reinduction i),
    Indication: Acute Lymphocytic Leukaemia

Cyclophosphamide
    Dosage: on day 26
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Dosage: l: 25 mg/m2/dose, s/h: 25 mg/m2/dose, days 1, 8

Methotrexate
    Dosage: age dependent dose on days 1

Methotrexate
    Dosage: high dose l:2.5 g/m2, s/h: 5 g/m2 on days 1, 15, 29, 43, 57

Vincristine
    Dosage: on days 1, 8, 15
    Indication: Acute Lymphocytic Leukaemia

Doxorubicin HCL
    Dosage: on days 1, 8
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: age dependent dose on days 8, 15, 29
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Dosage: days 15-70
    Indication: Acute Lymphocytic Leukaemia

Methotrexate
    Dosage: days 1, 15 (8, 22)

Cytarabine
    Dosage: days 23-26, 29-32
    Indication: Acute Lymphocytic Leukaemia

Mercaptopurine
    Dosage: days 22-35

Elspar
    Dosage: 10,000 u/m2 on 2,4,6,8,10,12, extra on 15, 17, 19 if 5% residual leukemia cells in bone marrow on 15

Dexamethasone
    Dosage: l: 8 mg/m2/day, 5 days: s/h: 12 mg/m2/day, 5 days ever 4 weeks
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Cotrim



Possible Mercaptopurine side effects in 13 year old female

Reported by a physician from United States on 2012-03-16

Patient: 13 year old female

Reactions: Viral Infection, Crohn's Disease, Drug Interaction, Pancytopenia, Off Label Use, Fatigue, Alopecia, Dizziness, Escherichia Sepsis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Omeprazole
    Dosage: 20 mg, 1x/day:qd

Mesalamine
    Dosage: unk, unknown
    Indication: Crohn's Disease

Omeprazole
    Dosage: unk, unknown
    Indication: Crohn's Disease

Mercaptopurine
    Dosage: unk, unknown
    Indication: Crohn's Disease

Other drugs received by patient: Budesonide



Possible Mercaptopurine side effects in 72 year old male

Reported by a physician from United States on 2012-01-24

Patient: 72 year old male

Reactions: Off Label Use, Rectal Cancer

Drug(s) suspected as cause:
Mesalamine

Mercaptopurine
    Dosage: 100 milligram;
    Administration route: Oral

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017